18889881171
Kalkine 0
countryflagUS

Atossa Genetics Inc

Healthcare US ATOS

0.83USD
-0.0211(2.48%)

Last update at 2025-06-17T17:00:00Z

Day Range

0.820.85
LowHigh

52 Week Range

0.702.31
LowHigh

Fundamentals

  • Previous Close 0.85
  • Market Cap158.51M
  • Volume215787
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.46200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -26.96000M -20.60600M -17.82795M -17.23978M -11.40493M
Minority interest - - - - -
Net income -26.22900M -20.60600M -21.09931M -17.23978M -11.40493M
Selling general administrative 12.61M 11.31M 8.00M 10.62M 7.22M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.00800M 0.02M 0.05M 0.05M 0.04M
Ebit -27.69900M -20.52100M -14.60739M -17.26543M -11.43423M
Ebitda -27.69100M -20.49800M -11.28951M -17.21264M -11.39004M
Depreciation and amortization 0.00800M 0.02M 3.32M 0.05M 0.04M
Non operating income net other 0.73M -0.08500M -2.28177M 0.03M 0.03M
Operating income -27.69100M -20.52100M -14.60739M -17.26543M -11.43423M
Other operating expenses 27.69M 20.52M 14.61M 17.27M 11.43M
Interest expense -0.00800M 0.09M 0.94M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income 0.88M - - - -
Net interest income 0.88M - -0.93879M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.73100M 0.09M 3.27M -0.02565M -0.02930M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 27.69M 20.52M 14.61M 17.27M 11.43M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.73M -0.08500M -3.22056M 0.03M 0.03M
Discontinued operations - - - - -
Net income from continuing ops -26.96000M -20.60600M -17.82795M -17.23978M -11.40493M
Net income applicable to common shares -26.96000M -20.60600M -22.33075M -17.23978M -22.88424M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 96.25M 123.53M 141.26M 42.84M 14.49M
Intangible assets - - - 0.01M 0.07M
Earning assets - - - - -
Other current assets 3.65M 2.42M 1.19M 0.66M 0.03M
Total liab 5.24M 5.57M 3.13M 15.67M 1.33M
Total stockholder equity 91.02M 117.96M 138.14M 27.17M 13.16M
Deferred long term liab - - - - -
Other current liab 4.43M 2.60M 1.41M 13.01M 0.01M
Common stock 22.79M 22.79M 22.79M 8.56M 1.64M
Capital stock - 22.79M 22.79M 8.56M 1.64M
Retained earnings -186.28800M -156.19400M -129.23400M -111.89899M -94.07104M
Other liab - - - - -
Good will - - - - -
Other assets - 0.64M 0.00200M 0.06M 0.00035M
Cash 88.57M 110.89M 136.38M 39.55M 12.58M
Cash and equivalents - - - - -
Total current liabilities 5.24M 5.57M 3.13M 15.67M 1.32M
Current deferred revenue - - - 1.06M 0.98M
Net debt -88.57000M -110.89000M -136.37700M -39.53562M -12.53066M
Short term debt - - - 0.02M 0.04M
Short long term debt - - - - -
Short long term debt total - - - 0.02M 0.05M
Other stockholder equity 254.51M 250.78M 244.58M 130.51M 105.58M
Property plant equipment - - 0.02M 0.04M 0.03M
Total current assets 92.22M 118.20M 141.24M 42.77M 14.32M
Long term investments - 4.70M - - -
Net tangible assets - 117.96M 137.55M 26.53M 13.16M
Short term investments - - - - -
Net receivables -0.00149M 0.74M 1.07M 0.63M 0.74M
Long term debt - - - - -
Inventory 1.49M 4.14M 2.60M 1.92M 0.97M
Accounts payable 0.81M 2.96M 1.72M 1.59M 0.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - -0.58200M - -0.15100M
Additional paid in capital - - - - -
Common stock total equity - 22.79M 22.79M 13.00M 1.64M
Preferred stock total equity - - - 0.00000M 0.00000M
Retained earnings total equity - -156.19400M -129.23400M -111.89899M -94.07104M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.32M 0.64M 0.00200M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 4.03M 5.33M 0.02M 0.07M 0.17M
Capital lease obligations - - 0.00000M 0.02M 0.05M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.72700M -0.00900M -0.00937M -0.00762M -0.11091M
Change to liabilities 2.44M 0.13M 1.30M -0.22204M 0.28M
Total cashflows from investing activities -4.72700M -0.00900M -0.00937M -0.00762M -0.11091M
Net borrowings - - - - -
Total cash from financing activities 0.00000M 113.30M 38.55M 11.34M 12.29M
Change to operating activities -1.84700M -1.28400M -1.40679M -0.73114M -0.08283M
Net income -26.96000M -20.60600M -17.82795M -17.23978M -11.40493M
Change in cash -25.48700M 96.82M 26.97M 2.20M 3.22M
Begin period cash flow 136.49M 39.66M 12.69M 10.49M 7.27M
End period cash flow 111.00M 136.49M 39.66M 12.69M 10.49M
Total cash from operating activities -20.76000M -16.47200M -11.57028M -9.12844M -8.96162M
Issuance of capital stock 0.00000M 69.67M 38.57M 0.00000M 12.29M
Depreciation 0.00800M 0.02M 0.05M 0.05M 0.04M
Other cashflows from investing activities -4.70000M - - - -
Dividends paid - - -4.50280M - -
Change to inventory - - - - -
Change to account receivables - - 0.10M - -
Sale purchase of stock - 44.21M 9.61M 11.34M 12.29M
Other cashflows from financing activities -4.72700M 43.64M 9.44M 11.34M -0.11091M
Change to netincome 6.79M 5.27M 6.32M 7.11M 1.05M
Capital expenditures 0.03M 0.00900M 0.00937M 0.00762M 0.11M
Change receivables - - - - -
Cash flows other operating -3.04100M -1.63200M -0.53958M 1.17M 1.07M
Exchange rate changes - - - - -
Cash and cash equivalents changes -25.48700M 96.82M 26.97M 2.20M 3.22M
Change in working capital -0.59900M -1.15600M -0.11135M -0.79130M -0.06441M
Stock based compensation 6.79M 5.27M 3.02M 8.84M 2.46M
Other non cash items 0.00300M 26.96M 0.94M 0.00581M -2.02571M
Free cash flow -20.78700M -16.48100M -11.57965M -9.13607M -9.07253M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ATOS
Atossa Genetics Inc		 -0.0211 2.48% 0.83 - - - 2.13 2.01
NVO
Novo Nordisk A/S		 -2.38 3.09% 74.64 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.16 4.04% 75.15 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.28 0.51% 448.63 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -3.845 0.74% 518.84 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Genetics Inc

107 Spring Street, Seattle, WA, United States, 98104

Key Executives

Name Title Year Born
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & Pres 1951
Mr. Kyle Guse CPA, Esq., CPA CFO, Gen. Counsel & Sec. 1964
Ms. Heather Rees VP of Fin. & Accounting NA
Ms. Delly Behen P.H.R. VP of Admin. & HR NA
Ms. Janet Rose Rea MSPH, RAC Sr. VP of Regulatory, Quality & Clinical Affairs NA
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer NA
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & President 1951
Ms. Heather Rees CPA Senior VP of Finance & Principal Accounting Officer 1973
Ms. Delly Behen P.H.R. Senior Vice President of Administration & HR NA
Mr. Eric Van Zanten Vice President of Investor & Public Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.